The DOI matches its Crossref record; 243 of the 243 references it cites were found in a registry or an index.
Targeting cell cycle regulation in cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–243 of 243
Hanse, E. A., Mashek, D. G., Becker, J. R., Solmonson, A., Mullany, L. K., Mashek, M. T., Towle, H. C., Chau, A. T., & Albrecht, J. H. (2012) · Cell Cycle · doi:10.4161/cc.21019 · Cited by 75
Enzymatic features of the glucose metabolism in tumor cells
Herling, A., König, M., Bulik, S., & Holzhütter, H. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08174.x · Cited by 74
E2F and the molecular mechanisms of early cell-cycle control
Thangue, N. B. L. (1996) · Biochemical Society Transactions · doi:10.1042/bst0240054 · Cited by 72
A skeleton model for the network of cyclin-dependent kinases driving the mammalian cell cycle
Gérard, C., & Goldbeter, A. (2010) · Interface Focus · doi:10.1098/rsfs.2010.0008 · Cited by 71
dan-yi, L., Zhu, Y., Tang, Q., Lu, H., Li, H., Yang, Y., Li, Z., & Tong, S. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2008.0494 · Cited by 69
Ma, Z., Yao, G., Zhou, B. O., Fan, Y., Gao, S., & Feng, X. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.999 · Cited by 68
Fbw7 Isoform Interaction Contributes to Cyclin E Proteolysis
Zhang, W., & Koepp, D. M. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0253 · Cited by 67
Albanese, C., Alzani, R., Amboldi, N., Avanzi, N. R., Ballinari, D., Brasca, M. G., Festuccia, C., Fiorentini, F., Locatelli, G., Pastori, W., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0190 · Cited by 66
Hoeferlin, L. A., Oleinik, N. V., Krupenko, N. I., & Krupenko, S. A. (2011) · Genes & Cancer · doi:10.1177/1947601911432495 · Cited by 66
Arkenau, H., Plummer, R., Molife, L. R., Olmos, D., Yap, T. A., Squires, M. S., Lewis, S., Lock, V., Yule, M., Lyons, J. F., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr451 · Cited by 65
Phase I study of terameprocol in patients with recurrent high-grade glioma
Grossman, S. A., Ye, X., Peereboom, D. M., Rosenfeld, M. R., Mikkelsen, T., Supko, J. G., & Desideri, S. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nor230 · Cited by 63
Cell Cycle Regulating Kinase Cdk4 as a Potential Target for Tumor Cell Treatment and Tumor Imaging
Graf, F., Koehler, L., Knieß, T., Wuest, F. R., Mosch, B., & Pietzsch, J. (2009) · Journal of Oncology · doi:10.1155/2009/106378 · Cited by 62
Boss, D. S., Schwartz, G. K., Middleton, M. R., Amakye, D. D., Swaisland, H., Midgley, R. S., Ranson, M., Danson, S. J., Calvert, H., Plummer, R., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp377 · Cited by 62
Siemeister, G., Luecking, U., Wagner, C., Detjen, K. M., Coy, C. M., & Bosslet, K. (2006) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2006.06.003 · Cited by 62
Deepa, P. R., Vandhana, S., Jayanthi, U., & Krishnakumar, S. (2012) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2011.00844.x · Cited by 60
Ma, W. W., Messersmith, W. A., Dy, G. K., Weekes, C. D., Whitworth, A., Ren, C., Maniar, M. L., Wilhelm, F. E., Eckhardt, S., Adjei, A. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2813 · Cited by 60
Bible, K. C., Peethambaram, P. P., Oberg, A. L., Maples, W. J., Groteluschen, D. L., Boente, M. P., Burton, J. K., Gomez‐Dahl, L. C., Tibodeau, J. D., Isham, C. R., et al. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.05.030 · Cited by 59
Riesterer, O., Matsumoto, F., Wang, L., Pickett, J., Molkentine, D. P., Giri, U. P., Milas, L., & Raju, U. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9361-2 · Cited by 56
FASCAPLYSIN as a Specific Inhibitor for CDK4: Insights from Molecular Modelling
Shafiq, M. I., Steinbrecher, T. B., & Schmid, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042612 · Cited by 52
Terret, C., Zanetta, S., Roche, H. H., Schellens, J. H. M., Faber, M. N., Wanders, J., Ravic, M., & Droz, J. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00128-x · Cited by 47
Matulonis, U. A., Lee, J., Lasonde, B., Tew, W. P., Yehwalashet, A., Matei, D. E., Behbakht, K., Grothusen, J., Fleming, G. F., Lee, N. K., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.07.020 · Cited by 46
Cell Cycle and Cancer: Genetic Analysis of the Role of Cyclin-dependent Kinases
Barbacid, M., Ortega, S., Sotillo, R., Odajima, J., Martín, A., Santamaría, D., Dubus, P. R., & Malumbres, M. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.005 · Cited by 45
Cdk2-Null Mice Are Resistant to ErbB-2-Induced Mammary Tumorigenesis
Ray, D., Terao, Y., Christov, K. T., Kaldis, P., & Kiyokawa, H. (2011) · Neoplasia · doi:10.1593/neo.101704 · Cited by 43
Shirsath, N., Manohar, S. M., & Joshi, K. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-77 · Cited by 43
McClue, S. J., & Stuart, I. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019232 · Cited by 43
Gorlick, R. G., Kolb, E. A., Houghton, P. J., Morton, C. L., Neale, G. A. M., Keir, S. T., Carol, H., Lock, R. B., Phelps, D. A., Kang, M. H., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24073 · Cited by 42
Lansdell, T. A., Hurchla, M. A., Xiang, J., Hovde, S., Weilbaecher, K. N., Henry, R. W., & Tepe, J. J. (2012) · ACS Chemical Biology · doi:10.1021/cb300568r · Cited by 35
Scott, E. N., Thomas, A., Molife, L. R., Ahmed, S. I., Blagden, S. P., Fong, P. C. C., Kowal, K., McCoy, C., Wiesinger, H., Steward, W. P., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0968-y · Cited by 34
Ramifications of a redox switch within a normal cell: Its absence in a cancer cell
Hoffman, A., SPETNER, L. M., & Burke, M. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.03.025 · Cited by 32
Zanuy, M., Ramos‐Montoya, A., Villacañas, Ó., Canela-Canela, N., Miranda, A., Aguilar, E., Agell, N., Bachs, O., Rubio, J., Pujol, M. D., et al. (2011) · Metabolomics · doi:10.1007/s11306-011-0328-x · Cited by 31
Self-citationWilkaniec, A., Czapski, G. A., Adamczyk, A., Gajkowska, B., & Strosznajder, J. B. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.11.018 · Cited by 31
Neste, E. V. D., Berghe, G., & Bontemps, F. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003703694 · Cited by 31
Caporali, S., Alvino, E., Levati, L., Esposito, A. I., Ciomei, M., Brasca, M. G., Bufalo, D. D., Desideri, M., Bonmassar, E., Pfeffer, U., et al. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.06.004 · Cited by 27
ESE‐3, an Ets family transcription factor, is up‐regulated in cellular senescence
Fujikawa, M., Katagiri, T., Tugores, A., Nakamura, Y., & Ishikawa, F. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00543.x · Cited by 27
A dual role of p21waf1/cip1 gene in apoptosis of HEp-2 treated with cisplatin or methotrexate
Pavelić, S. K., Čaćev, T., & Kralj, M. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.28 · Cited by 26
Phase I Clinical Trial of Repeat Dose Terameprocol Vaginal Ointment in Healthy Female Volunteers
Khanna, N., Dalby, R. N., Connor, A. L., Church, A., Stern, J., & Frazer, N. (2008) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e31816766af · Cited by 26
Díaz‐Moralli, S., Ramos‐Montoya, A., Marín, S., Fernández-Álvarez, A. J., Casado, M., & Cascante, M. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00675.2011 · Cited by 26
Self-citationBerkofsky‐Fessler, W., Nguyen, T. Q., Delmar, P., Molnos, J., Kanwal, C., DePinto, W., Rosinski, J., McLoughlin, P., Ritland, S., DeMario, M., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0083 · Cited by 25
Hikita, T., Oneyama, C., & Okada, M. (2010) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01439.x · Cited by 24
Ranjan, P., & Heintz, N. H. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.08.049 · Cited by 18
Transcriptional modulation of apoptosis regulators by roscovitine and related compounds
Garrofé-Ochoa, X., Cosialls, A. M., Ribas, J., Gil, J., & Boix, J. (2011) · APOPTOSIS · doi:10.1007/s10495-011-0603-3 · Cited by 16
ENMD-2076 for hematological malignancies
How, J., & Yee, K. W. L. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.668882 · Cited by 14
Cell Cycle: Bistability Is Needed for Robust Cycling
Ingolia, N. T. (2005) · Current Biology · doi:10.1016/j.cub.2005.11.012 · Cited by 12
Cited by
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets
Feitelson, M. A., Arzumanyan, A., Kulathinal, R. J., Blain, S. W., Holcombe, R. F., Mahajna, J., Marino, M., Martinez-Chantar, M. L., Nawroth, R., Sanchez-Garcia, I., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.006 · Cited by 778
How the Warburg effect supports aggressiveness and drug resistance of cancer cells?
Icard, P., Shulman, S., Farhat, D., Steyaert, J.-M., Alifano, M., & Lincet, H. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.03.001 · Cited by 643
Arsenic exposure: A public health problem leading to several cancers
Palma-Lara, I., Martínez-Castillo, M., Quintana-Pérez, J. C., Arellano-Mendoza, M. G., Tamay-Cach, F., Valenzuela-Limón, O. L., García-Montalvo, E. A., & Hernández-Zavala, A. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2019.104539 · Cited by 473
Interconnection between Metabolism and Cell Cycle in Cancer
Icard, P., Fournel, L., Wu, Z., Alifano, M., & Lincet, H. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.12.007 · Cited by 327
Essential Oils and Their Constituents as Anticancer Agents: A Mechanistic View
Gautam, N., Mantha, A. K., & Mittal, S. (2014) · BioMed Research International · doi:10.1155/2014/154106 · Cited by 288
Metadata
- Authors
- Diaz-Moralli, S., Tarrado-Castellarnau, M., Miranda, A., & Cascante, M.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 138
- Issue
- 2
- Pages
- 255-271
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W1976886432
- Cited by
- 361
- References
- 243
- FWCI
- 13.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.